How to appeal a UnitedHealthcare lymphoma & leukemia (heme malignancies) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for lymphoma & leukemia (heme malignancies)

Cited policy: OptumRx Brukinsa (Zanubrutinib) Prior Authorization

CLL/SLL, MCL ≥1 prior therapy, WM, MZL ≥1 prior anti-CD20, FL ≥2 prior systemic therapies. Hematologist-oncologist Rx. 320 mg PO daily (160 BID or 320 once daily). Reauth at 6-12 mo with response per iwCLL 2018 / Lugano.

How UnitedHealthcare denies lymphoma & leukemia (heme malignancies) — and how to counter it

Where UnitedHealthcare pushes back: 1) Step therapy: must fail Imbruvica first; 2) Brukinsa restricted to MCL only — not CLL; 3) Atrial fibrillation must be documented before switch; 4) Cost vs ibrutinib.

Counter-arguments that hold up: ALPINE (Hillmen NEJM 2023;388:319-332) — zanubrutinib SUPERIOR PFS + lower atrial fibrillation (4.6% vs 12.0%) + lower cardiac event discontinuation vs ibrutinib in r/r CLL. SEQUOIA (Tam Lancet Oncol 2022;23:1031) — zanubrutinib 1L CLL incl. del(17p) cohort. FDA Jan 19, 2023 CLL approval (1L and r/r). NCCN CLL v3.2024 lists all 3 BTKis (acalabrutinib / zanubrutinib / ibrutinib) as preferred — ibrutinib is NOT mandated first. Pre-existing cardiac comorbidity (afib / HTN / CAD) is a positive indication for zanubrutinib OR acalabrutinib over ibrutinib.

What UnitedHealthcare typically denies for lymphoma & leukemia (heme malignancies)

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For lymphoma & leukemia (heme malignancies), expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the lymphoma & leukemia (heme malignancies) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Imbruvica
• Calquence
• Brukinsa
• Jaypirca / pirtobrutinib
• Venclexta
• Rituxan / rituximab

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.